BAL PHARMA LTD.
BALPHARMA · General/Diversified · NSE
₹85
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for BALPHARMA yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
23%
ROE
9.3%
Debt/Equity
1.94
WACC
11.1%
Market Cap
₹135.53 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
12.9%
Return on capital employed
EV / EBITDA
11.9×
Enterprise multiple
Debt / EBITDA
6.6×
Leverage vs earnings
Interest Coverage
1.4×
EBIT covers interest
Current Ratio
1.07×
Short-term liquidity
Asset Turnover
0.92×
Revenue per ₹ of assets
Revenue CAGR (3Y)
1.1%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
Ratio Trends
BALPHARMA · last 7 annual periods
ROE
9.3%
ROCE
12.9%
Operating Margin
—
Debt / Equity
1.94×
PE
41.5×
EV / EBITDA
9.8×
Historical Financials
BALPHARMA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 NSE_XBRL | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹251 Cr | ₹280 Cr | ₹302 Cr | ₹339 Cr | ₹303 Cr | +4.9% |
| EBITDA | — | ₹27.1 Cr | ₹24.4 Cr | ₹33.6 Cr | ₹29.4 Cr | +2.1% |
| EBIT | ₹16.1 Cr | ₹19.6 Cr | ₹16.9 Cr | ₹24.3 Cr | — | +10.9% |
| PAT | ₹4.7 Cr | ₹5.6 Cr | ₹2.6 Cr | ₹7.4 Cr | ₹7.2 Cr | +11.2% |
| EPS (diluted) | ₹3.34 | ₹3.71 | ₹1.68 | ₹4.96 | — | +10.4% |
| CFO | ₹22.2 Cr | ₹26.8 Cr | ₹-1.5 Cr | ₹22.8 Cr | ₹20.3 Cr | -2.2% |
| CapEx | — | ₹-8.5 Cr | ₹-14.6 Cr | ₹-11.0 Cr | ₹-18.8 Cr | — |
| FCF | — | ₹18.3 Cr | ₹-16.2 Cr | ₹11.8 Cr | ₹1.5 Cr | -46.3% |
| Total Assets | — | ₹261 Cr | ₹313 Cr | ₹320 Cr | ₹336 Cr | +6.5% |
| Total Debt | — | ₹107 Cr | ₹133 Cr | ₹142 Cr | ₹150 Cr | +9.0% |
| Shareholders' Equity | — | ₹58.6 Cr | ₹63.8 Cr | ₹72.0 Cr | ₹77.4 Cr | +7.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
BALPHARMA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
KREBSBIO KREBSBIO | — | — | Pending | 10.4% | — |
ALPA ALPA | — | — | Pending | 11.4% | — |
NATCAPSUQ NATCAPSUQ | — | — | Pending | 0.3% | — |
PAR PAR | — | — | Pending | 13.5% | — |
BROOKS BROOKS | — | — | Pending | -10.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
9 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹5.40/sh
Last payout
2025-09-18
₹1.20
Peak payout
₹1.20
Trailing yield
1.41%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of BALPHARMA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for BALPHARMA →
Compare
Head-to-head with peers
Compare BALPHARMA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse BALPHARMANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.